{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:46:19Z","timestamp":1789757179781,"version":"4.0.1"},"reference-count":63,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer\/testis antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a nuclear receptor and transcriptional regulator, PRAME plays a critical role in inhibiting retinoic acid signalling, which is essential for cell differentiation and proliferation. Its aberrant overexpression in various malignancies, particularly cutaneous melanoma, is associated with more aggressive tumour phenotypes, positioning PRAME as both a diagnostic and prognostic marker. In melanoma, PRAME is typically highly expressed, in contrast to its weak or absent expression in benign nevi, thereby improving the accuracy of differential diagnoses. The diagnostic value of PRAME extends to various lesions. It is significantly expressed in uveal melanoma, correlating to an increased risk of metastasis. In acral melanomas, especially those with histopathological ambiguity, PRAME helps to improve diagnostic accuracy. However, its expression in spitzoid and ungual melanocytic lesions is inconsistent and requires a comprehensive approach for an accurate assessment. In soft tissue sarcomas, PRAME may be particularly helpful in differentiating melanoma from clear cell sarcoma, an important distinction due to their similar histological appearance but different treatment approaches and prognosis, or in detecting dedifferentiated and undifferentiated melanomas. In non-melanoma skin cancers such as basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma, the variable expression of PRAME can lead to diagnostic complexity. Despite these challenges, the potential of PRAME as a therapeutic target in melanoma is significant. Emerging immunotherapies, including T-cell-based therapies and vaccines targeting PRAME, are being investigated to exploit its cancer-specific expression. Ongoing research into the molecular role and mechanism of action of PRAME in skin cancer continues to open new avenues in both diagnostics and therapeutics, with the potential to transform the management of melanoma and related skin cancers.<\/jats:p>","DOI":"10.3390\/ijms25031582","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:57:07Z","timestamp":1706504227000},"page":"1582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-1122","authenticated-orcid":false,"given":"Fortunato","family":"Cassalia","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Danese","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Integrated Medical and General Activity, University of Verona, 37100 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Tudurachi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Federico","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Magna Graecia, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zambello","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Guidotti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Franceschin","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bolzon","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ospedale San Bortolo, 36100 Vicenza, Italy"},{"name":"Centro Studi Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED), 24121 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-0775","authenticated-orcid":false,"given":"Anna","family":"Belloni Fortina","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"},{"name":"Pediatric Dermatology Department of Women\u2019s and Child\u2019s Health (SDB), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"ref_1","first-page":"334","article-title":"Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target","volume":"3","author":"Bose","year":"2023","journal-title":"Int. J. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e12770","DOI":"10.1111\/cpr.12770","article-title":"The Role of the Cancer Testis Antigen PRAME in Tumorigenesis and Immunotherapy in Human Cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/Testis Antigens, Gametogenesis and Cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.0501564102","article-title":"The Gene Expression Signatures of Melanoma Progression","volume":"102","author":"Haqq","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.leukres.2007.12.010","article-title":"PRAME Expression in Hairy Cell Leukemia","volume":"32","author":"Arons","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1568009616666151222151818","article-title":"Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins","volume":"16","author":"Hermes","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/gcc.20465","article-title":"Hypomethylation of PRAME Is Responsible for Its Aberrant Overexpression in Human Malignancies","volume":"46","author":"Schenk","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1476-4598-9-226","article-title":"Leucine-Rich Repeat Protein PRAME: Expression, Potential Functions and Clinical Implications for Leukaemia","volume":"9","author":"Wadelin","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1073\/pnas.84.20.7174","article-title":"Mapping of Four Distinct BCR-Related Loci to Chromosome Region 22q11: Order of BCR Loci Relative to Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia Breakpoints","volume":"84","author":"Croce","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/366751a0","article-title":"Crystal Structure of Porcine Ribonuclease Inhibitor, a Protein with Leucine-Rich Repeats","volume":"366","author":"Kobe","year":"1993","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","first-page":"954","article-title":"Upregulation of SOX9 Inhibits the Growth of Human and Mouse Melanomas and Restores Their Sensitivity to Retinoic Acid","volume":"119","author":"Passeron","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2017.06.015","article-title":"Tumor Antigen PRAME Is Up-Regulated by MZF1 in Cooperation with DNA Hypomethylation in Melanoma Cells","volume":"403","author":"Lee","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_16","first-page":"2861","article-title":"Novel Gene Signature for Predicting Biochemical Recurrence-Free Survival of Prostate Cancer and PRAME Modulates Prostate Cancer Progression","volume":"13","author":"Kadeerhan","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1007\/s11033-023-08290-y","article-title":"Quantitative Expression Evaluation of PRAME Gene in Osteosarcoma","volume":"50","author":"Petrilli","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hedrich, V., Breitenecker, K., Ortmayr, G., Pupp, F., Huber, H., Chen, D., Sahoo, S., Jolly, M.K., and Mikulits, W. (2023). PRAME Is a Novel Target of Tumor-Intrinsic Gas6\/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15092415"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.14904","article-title":"Diagnostic Test Accuracy Meta-Analysis of PRAME in Distinguishing Primary Cutaneous Melanomas from Benign Melanocytic Lesions","volume":"83","author":"Kunc","year":"2023","journal-title":"Histopathology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_21","first-page":"2208","article-title":"Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study","volume":"11","author":"Pujol","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1111\/jcmm.16967","article-title":"Cancer Testis Antigen PRAME: An Anti-Cancer Target with Immunomodulatory Potential","volume":"25","author":"Naik","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00428-023-03629-z","article-title":"Immunohistochemical Expression of PRAME in 485 Cases of Epithelial Tubo-Ovarian Tumors","volume":"483","author":"Laco","year":"2023","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-Testis Antigens PRAME and NY-ESO-1 Correlate with Tumour Grade and Poor Prognosis in Myxoid Liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_25","first-page":"1238","article-title":"Expression of Cancer-Testis Antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in Myxoid and Round Cell Liposarcoma","volume":"27","author":"Hemminger","year":"2014","journal-title":"Mod. Pathol. Off. J. US Can. Acad. Pathol. Inc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/cup.14012","article-title":"Preferentially Expressed Antigen in Melanoma Expression in Nonmelanoma Skin Cancers and Melanocytes in Surrounding Skin","volume":"48","author":"Elsensohn","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3324\/haematol.13214","article-title":"The Relevance of Preferentially Expressed Antigen of Melanoma (PRAME) as a Marker of Disease Activity and Prognosis in Acute Promyelocytic Leukemia","volume":"93","author":"Balanzategui","year":"2008","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16779","DOI":"10.1007\/s00432-023-05423-5","article-title":"Identification of a Novel Five Ferroptosis-Related Gene Signature as a Promising Prognostic Model for Breast Cancer","volume":"149","author":"Cheng","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, J., Yin, J., Zhong, J., Yang, Z., Tang, A., and Li, S. (2020). Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/8828579"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/1566524021666211027091719","article-title":"A Systematic Review of Potential Immunotherapies Targeting PRAME in Retinoid Resistant Oral Potentially Malignant Disorders and Oral Cancer","volume":"22","author":"Dwivedi","year":"2022","journal-title":"Curr. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/mco.2023.2691","article-title":"Investigating Chimeric Antigen Receptor T Cell Therapy and the Potential for Cancer Immunotherapy (Review)","volume":"19","author":"Poojary","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1021\/acsbiomaterials.3c01154","article-title":"Advances in Cancer Vaccine Research","volume":"9","author":"Liu","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/DAD.0000000000001885","article-title":"Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms","volume":"43","author":"Googe","year":"2021","journal-title":"Am. J. Dermatopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gosman, L.M., \u021a\u0103poi, D.-A., and Costache, M. (2023). Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115881"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0000000000002032","article-title":"PRAME Expression in Mucosal Melanoma of the Head and Neck Region","volume":"47","author":"Ricci","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_39","first-page":"1727","article-title":"Analyses of Molecular and Histopathologic Features and Expression of PRAME by Immunohistochemistry in Mucosal Melanomas","volume":"32","author":"Toyama","year":"2019","journal-title":"Mod. Pathol. Off. J. US Can. Acad. Pathol. Inc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cup.14130","article-title":"Preferentially Expressed Antigen in Melanoma and P16 Expression in Acral Melanocytic Neoplasms","volume":"49","author":"McBride","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjd.15803","article-title":"Acral Lentiginous Melanoma: A Skin Cancer with Unfavourable Prognostic Features. A Study of the German Central Malignant Melanoma Registry (CMMR) in 2050 Patients","volume":"178","author":"Teramoto","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12964-023-01197-y","article-title":"Intrinsic Disorder in PRAME and Its Role in Uveal Melanoma","volume":"21","author":"Antonietti","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"154543","DOI":"10.1016\/j.prp.2023.154543","article-title":"Immunohistochemical Expression of PRAME Is a Marker of Poor Prognosis in Uveal Melanoma: A Clinico-Pathologic and Immunohistochemical Study on a Series of 85 Cases","volume":"247","author":"Broggi","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/his.14452","article-title":"PRAME Expression in Melanocytic Lesions of the Conjunctiva","volume":"79","author":"Hawlina","year":"2021","journal-title":"Histopathology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2023.02.002","article-title":"PRAME Expression by Immunohistochemistry and Reverse Transcription Quantitative PCR in Conjunctival Melanocytic Lesions-a Comprehensive Clinicopathologic Study of 202 Cases and Correlation of Cytogenetics with PRAME Expression in Challenging Conjunctival Melanocytic Lesions","volume":"134","author":"Mudhar","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.pathol.2023.08.003","article-title":"Characterisation of the Protein Expression of the Emerging Immunotherapy Targets VISTA, LAG-3 and PRAME in Primary Uveal Melanoma: Insights from a Southern French Patient Cohort","volume":"55","author":"Lamas","year":"2023","journal-title":"Pathology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cup.14226","article-title":"PRAME Expression in Melanocytic Lesions of the Nail","volume":"49","author":"Parra","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13000-022-01218-3","article-title":"Cyclin D1 and PRAME Expression in Distinguishing Melanoma in Situ from Benign Melanocytic Proliferation of the Nail Unit","volume":"17","author":"Kim","year":"2022","journal-title":"Diagn. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/DAD.0000000000002156","article-title":"Preferentially Expressed Nuclear Antigen in Melanoma Expression in Melanocytic Activation (Melanotic Macule) of the Nail Unit. A Potential Diagnostic Pitfall? A Study of 3 Cases","volume":"44","author":"Perrin","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/DAD.0000000000002143","article-title":"Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus","volume":"44","author":"Krajisnik","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/PAS.0000000000001878","article-title":"Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions","volume":"46","author":"Santandrea","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cup.14290","article-title":"Diagnostic Utility of PRAME Expression by Immunohistochemistry in Subungual and Non-Subungual Acral Melanocytic Lesions","volume":"49","author":"Rothrock","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/cup.13818","article-title":"PRAME Expression in Melanocytic Proliferations with Intermediate Histopathologic or Spitzoid Features","volume":"47","author":"Raghavan","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cup.14245","article-title":"PRAME Immunohistochemistry of Spitzoid Neoplasms","volume":"49","author":"Koh","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1265827","DOI":"10.3389\/fmed.2023.1265827","article-title":"PRAME Immunohistochemistry Compared to Traditional FISH Testing in Spitzoid Neoplasms and Other Difficult to Diagnose Melanocytic Neoplasms","volume":"10","author":"Warbasse","year":"2023","journal-title":"Front. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/DAD.0000000000002208","article-title":"PRAME Expression Correlates with Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms","volume":"44","author":"Gerami","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cup.14342","article-title":"Combined Utility of P16 and BRAF V600E in the Evaluation of Spitzoid Tumors: Superiority to PRAME and Correlation with FISH","volume":"50","author":"McAfee","year":"2023","journal-title":"J. Cutan. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00428-023-03606-6","article-title":"PRAME Immunohistochemistry in Soft Tissue Tumors and Mimics: A Study of 350 Cases Highlighting Its Imperfect Specificity but Potentially Useful Diagnostic Applications","volume":"483","author":"Cammareri","year":"2023","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cazzato, G., Colagrande, A., Ingravallo, G., Lettini, T., Filoni, A., Ambrogio, F., Bonamonte, D., Dellino, M., Lupo, C., and Casatta, N. (2022). PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236936"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Cassalia, F., Cavallin, F., Danese, A., Del Fiore, P., Di Prata, C., Rastrelli, M., Belloni Fortina, A., and Mocellin, S. (2023). Soft Tissue Sarcoma Mimicking Melanoma: A Systematic Review. Cancers, 15.","DOI":"10.20944\/preprints202306.1545.v1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/his.14814","article-title":"PRAME Is a Useful Marker for the Differential Diagnosis of Melanocytic Tumours and Histological Mimics","volume":"82","author":"Chen","year":"2023","journal-title":"Histopathology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.pathol.2022.03.003","article-title":"PRAME Immunostain Expression in Sebaceous Lesions, Cutaneous Carcinomas and Adnexal Structures","volume":"54","author":"Ng","year":"2022","journal-title":"Pathology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:16Z","timestamp":1760104216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031582"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031582","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]}}}